This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - ARE, LPS, UTHR, GCO And GWRE Traded By Insiders

United Therapeutics Corporation (UTHR) - FREE Research Report

Rothblatt Martine A who is Ceo at United Therapeutics Corporation sold 18,149 shares at $109.85 on Dec. 23, 2013. Following this transaction, the Ceo owned 630,333 shares meaning that the stake was reduced by 2.8% with the 18,149-share transaction.

The shares most recently traded at $113.90, up $4.05, or 3.55% since the insider transaction. Historical insider transactions for United Therapeutics Corporation go as follows:

  • 24-Week # shares sold: 1,000

The average volume for United Therapeutics Corporation has been 574,900 shares per day over the past 30 days. United Therapeutics Corporation has a market cap of $4.4 billion and is part of the health care sector and drugs industry. Shares are up 114.36% year-to-date as of the close of trading on Monday.

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. The company has a P/E ratio of 16.0. Currently there are 3 analysts that rate United Therapeutics Corporation a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UTHR - FREE

TheStreet Quant Ratings rates United Therapeutics Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full United Therapeutics Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 16,558.94 +159.27 0.97%
S&P 500 1,933.21 +29.20 1.53%
NASDAQ 4,392.3840 +76.31 1.77%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs